EU committee backs dosing changes for Bristol-Myers Squibb’s immunotherapy

A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today.

The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for patients with advanced melanoma and previously-treated renal cell carcinoma. The committee also backed a shorter dosing option of 240-mg infused over 30 minutes every two weeks for Opdivo’s six approved monotherapy indications in the EU.

Get the full story at our sister site, Drug Delivery Business News.

The post EU committee backs dosing changes for Bristol-Myers Squibb’s immunotherapy appeared first on MassDevice.

from MassDevice https://ift.tt/2uk3mq3